Categories: News

iTolerance, Inc. to Present at Virtual Investor 2022 Top Picks Conference

Live video webcast presentation on Wednesday, January 26th at 3:00 PM ET

MIAMI, FL / ACCESSWIRE / January 19, 2022 / iTolerance, Inc. (“iTolerance” or the “Company”), a biotechnology company focused on the development of innovative regenerative medicines, today announced that Anthony Japour, CEO of iTolerance will present at the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 3:00 PM ET.

As part of the virtual event, the Company will provide a brief presentation, followed by a moderated discussion and an interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.

A live video webcast of the presentation will be available on the Events page of the Company’s website (itolerance.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

About iTolerance, Inc.

iTolerance is a privately held biotechnology company focused on the development of innovative regenerative medicines. The Company’s lead program, iTOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 Diabetes. iTOL-101 has demonstrated compelling efficacy in non-human primate studies. The Company plans to advance iTOL-101 towards an IND and first-in-human study. Additionally, the Company is advancing its regenerative cell therapy platform to fuel a robust pipeline addressing high-value indications. For more information, please visit itolerance.com.

Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
iTolerance@jtcir.com

SOURCE: iTolerance, Inc.

View source version on accesswire.com:
https://www.accesswire.com/684479/iTolerance-Inc-to-Present-at-Virtual-Investor-2022-Top-Picks-Conference

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

3 hours ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

3 hours ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

3 hours ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

3 hours ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

3 hours ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

6 hours ago